Skip to main content
logo
NewAmsterdam Pharma Company N.V. (NAMS)
NASDAQ: NAMS · Real-Time Price · USD
30.41
-2.42 (-7.39%)
At close: Mar 3, 2026, 4:00 PM EST
30.45
+0.04 (0.15%)
Pre-market: Mar 4, 2026, 4:28 AM EST

NAMS Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
22.545.5614.09102.69-
Revenue Growth (YoY)
-50.61%223.37%-86.28%--
Gross Profit
22.545.5614.09102.69-
Selling, General & Admin
106.3570.4537.6319.515.46
Research & Development
141.83151.41159.4286.7428.47
Total Operating Expenses
248.19221.85197.06106.2533.93
Operating Income
-225.68-176.29-182.97-3.56-33.93
Interest Income
27.5916.8811.28-0.01
Interest Expense
----0.29-0.25
Other Non-Operating Income (Expense)
-5.73-82.19-5.23-18.791.64
Total Non-Operating Income (Expense)
21.86-65.316.06-19.081.41
Pretax Income
-203.82-241.6-176.91-22.63-32.52
Provision for Income Taxes
--00.03--
Net Income
-203.82-241.6-176.94-22.63-32.52
Net Income to Common
-203.82-241.6-176.94-22.63-32.52
Shares Outstanding (Basic)
11894821924
Shares Outstanding (Diluted)
11894821924
Shares Change (YoY)
25.50%14.84%333.20%-19.76%156.56%
EPS (Basic)
-1.72-2.56-2.15-1.19-1.38
EPS (Diluted)
-1.72-2.56-2.15-1.19-1.38
Free Cash Flow
-148.03-159.24-141.2410.44-28.64
Free Cash Flow Per Share
-1.25-1.69-1.720.55-1.21
Gross Margin
100.00%100.00%100.00%100.00%-
Operating Margin
-1002.90%-386.91%-1298.56%-3.46%-
Profit Margin
-905.74%-530.25%-1255.76%-22.04%-
FCF Margin
-657.82%-349.49%-1002.43%10.17%-
EBITDA
-225.46-176.18-182.96-3.55-33.91
EBITDA Margin
-1001.92%-386.66%-1298.47%-3.45%-
EBIT
-225.68-176.29-182.97-3.56-33.93
EBIT Margin
-1002.90%-386.91%-1298.56%-3.46%-
Effective Tax Rate
0.00%0.00%-0.02%0.00%0.00%
Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q